Prostate Cancer Screening: A New Era of Precision and Reduced Anxiety
The landscape of prostate cancer screening is rapidly evolving, with advancements showcased at the European Association of Urology Congress (EAU26) in London. From increasingly accurate diagnostic tools to strategies for minimizing patient anxiety, the focus is shifting towards more personalized and effective care.
The Long-Term Benefits of Screening Confirmed
Decades of data from the Gothenburg 1 study, initiated in 1994, provide compelling evidence of the long-term benefits of prostate cancer screening. The study, involving 20,000 men, demonstrated that screening averts one death for every 311 men invited after 15 years, improving to one death averted for every 161 men after 30 years. Screening helped avert one death for every 13 men diagnosed after 15 years and one for every 6 men diagnosed after 30 years.
Though, researchers acknowledge the challenge of overdiagnosis – detecting cancers that would not have caused harm during a man’s lifetime. Dr. Jonas Hugosson of the University of Gothenburg noted that modern diagnostic pathways, incorporating MRI and risk stratification, are helping to address this issue.
MRI: Becoming Smarter and More Targeted
MRI is emerging as a crucial tool in prostate cancer screening, but standardization of its use is key. Twenty-one experts from Europe and North America have reached a consensus on best practices, outlined in the PRISM recommendations. These guidelines detail when and how to utilize MRI effectively, interpret results, and determine the need for biopsies and follow-up scans.
The landmark TRANSFORM trial will implement these recommendations, utilizing 10-minute, non-contrast ‘Prostagram’ MRI scans to screen up to 300,000 men. Nikhil Mayor of Imperial College London emphasized the hope that standardized protocols will improve the accuracy and efficiency of screening programs.
Reducing Unnecessary Referrals with Risk Stratification
Preliminary data from the PRAISE-U study indicates that incorporating risk stratification alongside PSA testing can significantly reduce unnecessary MRI referrals – by 40–60%. Five European pilot sites are implementing algorithms that consider factors beyond PSA, such as PSA density or the Rotterdam Prostate Cancer Risk calculator (RPCRC), to identify men at lower risk who may not require immediate MRI scans. Centres using the RPCRC with transrectal ultrasound saw the greatest reduction in unnecessary MRIs.
Meike van Harten of Erasmus MC Cancer Institute highlighted the potential to alleviate the burden on imaging services and ensure timely access to diagnosis for those most in need.
Stockholm3: A Biomarker-Based Approach for Precision Screening
The Stockholm3 blood test, which combines protein and genetic biomarkers with clinical information, is demonstrating promising results in reducing unnecessary testing. A Swedish trial found that using Stockholm3 before MRI in men with a PSA of 2 ng/ml or higher led to a 67% reduction in MRI scans.
Professor Ugo Falagario of the University of Foggia, Italy, noted that the test can help identify men with potentially higher-risk cancers, streamlining the diagnostic process and reducing demand on imaging services.
Addressing Patient Anxiety During Screening
Research presented at EAU26 also addressed the psychological impact of prostate cancer screening. A study of 692 men with elevated PSA levels found that around a quarter experienced worry in the lead-up to biopsy, but severe anxiety was relatively rare, affecting 3.8–4.8% of men after referral for MRI, and biopsy. The greatest distress was reported immediately before biopsy, with 9.7% of men experiencing distress and 26% feeling worried, impacting daily life for 4.2%.
Dr. Linda Svensson, a specialist nurse in oncology, emphasized that while worry is natural, severe anxiety symptoms are uncommon, suggesting a low risk of psychological harm from modern screening programs.
Frequently Asked Questions
Q: What is PSA testing?
A: PSA testing measures the level of prostate-specific antigen in the blood, which can be elevated in men with prostate cancer.
Q: What is MRI used for in prostate cancer screening?
A: MRI helps to visualize the prostate gland and identify suspicious areas that may require further investigation.
Q: What is risk stratification?
A: Risk stratification involves assessing a man’s individual risk factors for prostate cancer to determine the most appropriate screening and diagnostic approach.
Q: Is prostate cancer screening always necessary?
A: The decision to undergo prostate cancer screening should be made in consultation with a healthcare professional, considering individual risk factors and preferences.
Q: What is the Stockholm3 test?
A: Stockholm3 is a biomarker-based blood test that combines protein and genetic biomarkers with clinical information to improve the accuracy of prostate cancer detection.
Did you know? The benefits of prostate cancer screening increase over time, with studies showing a greater reduction in mortality with longer follow-up periods.
Pro Tip: Discuss your individual risk factors and screening options with your doctor to make an informed decision about prostate cancer screening.
Stay informed about the latest advancements in prostate cancer screening and talk to your healthcare provider about what’s right for you. Explore additional resources on the European Association of Urology website.
Related reading